Suppliers / Abbvie

Abbvie

United Arab Emirates ABBV 57,000 employees 6 duplicate records merged Updated 9 July 2026

Abbvie is an API and finished-dose manufacturer based in United Arab Emirates. It holds 7 active US drug master files and 6 valid CEPs across a filed portfolio of 8 molecules. Its filings concentrate with Health Canada, US FDA and EMA. Its GMP standing is certified by EAEU_EEC, ZLG (DE) and HSA (SG), among 14 authorities. Its most recent recorded inspection, by US FDA, closed on 3 March 2026 as NAI.

7
active US DMFs
6
valid CEPs
12
registered plants
3,759
filings across 50 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
0 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 3 March 2026 NAI US FDA
  • 5 September 2025 NAI US FDA
  • 21 August 2025 NAI US FDA
  • 12 June 2025 NAI US FDA
  • 18 June 2024 VAI US FDA
  • 19 April 2024 NAI US FDA
  • 30 October 2023 VAI US FDA
  • 12 May 2023 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
North Chicago, United Arab Emirates Not on file
Pringy, United Arab Emirates Not on file
Westport, United Arab Emirates Not on file
Texas 76712, United Arab Emirates Not on file
HIMACHAL PRADESH, United Arab Emirates Not on file
Ludwigshafen, United Arab Emirates Not on file

6 further sites are on record.

What they file, and where

Filings and GMP by regulator

Regulator Filings GMP certificates
Health Canada 451 None
US FDA 390 5
EMA 252 9
INFARMED (PT) 250 None
FAMHP (BE) 167 None
AIFA (IT) 162 None
EAEU_EEC None 15
ZLG (DE) None 14
HSA (SG) None 12
NAFDAC (NG) None 12
ANSM (FR) None 9
MFDS (Korea) None 6
TMDA (TZ) None 5
MHRA (UK) None 5
FDA (GH) None 4
NCELS (KZ) None 4
ANVISA (Brazil) None 3
SAHPRA (ZA) None 3

Scale

Year Revenue Exports Destinations
2025 $16.6B Not reported Not reported
2024 $15.1B Not reported Not reported
2023 $14.3B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Abbvie comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 91 active litigation matters are on record.
  • The most recent inspection outcome was NAI, on 3 March 2026.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported